GLP-1 Brands: Every FDA-Approved and Compounded Option Compared (2026 Complete Guide)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Seven FDA-approved GLP-1 medications exist as of April 2026: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon)
• Compounded semaglutide and tirzepatide became widely available during the 2022-2026 FDA shortage period and remain legal alternatives when shortages persist
• Tirzepatide shows superior weight loss (15-22% total body weight) compared to semaglutide (10-15%) and older GLP-1 agonists (5-8%) in head-to-head trials
• Brand-name GLP-1 medications cost $900-$1,350 per month without insurance; compounded versions cost $250-$450 per month through telehealth platforms

Direct answer (40-60 words)

GLP-1 brands fall into three generations: older daily or weekly injectables (liraglutide, dulaglutide, exenatide), current standard-of-care semaglutide (Ozempic, Wegovy), and dual-agonist tirzepatide (Mounjaro, Zepbound). Compounded versions of semaglutide and tirzepatide exist as legal alternatives during FDA shortages. Each differs in efficacy, dosing frequency, side effects, and cost.

Table of contents

1. The complete landscape: FDA-approved GLP-1 brands by generation
2. Semaglutide brands: Ozempic vs Wegovy vs Rybelsus
3. Tirzepatide brands: Mounjaro vs Zepbound
4. Older GLP-1 brands: liraglutide, dulaglutide, exenatide
5. Compounded GLP-1: legal status and quality considerations
6. Head-to-head efficacy: which brand produces the most weight loss
7. The FormBlends Brand Selection Framework: matching patient to medication
8. What most articles get wrong about "off-label" prescribing
9. Side effect profiles compared across brands
10. Cost comparison: brand-name vs compounded in 2026
11. When brand-name is worth the premium (and when it's not)
12. FAQ
13. Sources

The complete landscape: FDA-approved GLP-1 brands by generation

The GLP-1 receptor agonist class has evolved across three distinct generations, each representing a meaningful advance in efficacy, tolerability, or convenience.

Generation 1 (2005-2014): Daily and twice-daily injectables

• Exenatide (Byetta): twice-daily injection, approved 2005
• Liraglutide (Victoza): once-daily injection, approved 2010
• Exenatide extended-release (Bydureon): once-weekly injection, approved 2012

These medications established proof-of-concept for GLP-1 therapy but required daily dosing (except Bydureon) and produced modest weight loss (5-8% total body weight). They remain on the market primarily for patients who've been stable on them for years.

Generation 2 (2014-2021): Weekly injectables with improved efficacy

• Dulaglutide (Trulicity): once-weekly injection, approved 2014
• Semaglutide (Ozempic for diabetes, Wegovy for obesity): once-weekly injection, approved 2017 (Ozempic) and 2021 (Wegovy)
• Semaglutide oral (Rybelsus): daily tablet, approved 2019

Semaglutide represented a step-change in weight-loss efficacy, producing 10-15% total body weight loss in the STEP trial program. Weekly dosing improved adherence. Rybelsus offered the first oral GLP-1 option, though with lower bioavailability than injectable forms.

Generation 3 (2022-present): Dual and triple agonists

• Tirzepatide (Mounjaro for diabetes, Zepbound for obesity): once-weekly injection, approved 2022 (Mounjaro) and 2023 (Zepbound)

Tirzepatide activates both GLP-1 and GIP receptors, producing 15-22% total body weight loss in the SURMOUNT trials. This dual mechanism represents the current state-of-the-art. Triple agonists (GLP-1/GIP/glucagon) are in Phase 3 trials as of 2026 but not yet approved.

Semaglutide brands: Ozempic vs Wegovy vs Rybelsus

All three contain the same active ingredient (semaglutide) but differ in FDA indication, dosing, and delivery method.

Brand	Indication	Delivery	Dosing schedule	Maintenance dose	Monthly cost (list price)
Ozempic	Type 2 diabetes	Subcutaneous injection	Weekly	0.5 mg, 1 mg, or 2 mg	$968
Wegovy	Chronic weight management	Subcutaneous injection	Weekly	2.4 mg	$1,349
Rybelsus	Type 2 diabetes	Oral tablet	Daily	7 mg or 14 mg	$935

Ozempic is FDA-approved only for type 2 diabetes but is widely prescribed off-label for weight loss at doses up to 2 mg weekly. The SUSTAIN trial program showed 5-7% weight loss at the 1 mg dose in diabetic patients (Sorli et al., Diabetes Care 2017).

Wegovy is the same molecule at a higher dose (2.4 mg weekly), FDA-approved specifically for obesity. The STEP 1 trial showed 14.9% mean weight loss at 68 weeks vs 2.4% for placebo (Wilding et al., New England Journal of Medicine 2021). Wegovy was on the FDA shortage list from March 2022 through October 2023, which drove demand for compounded semaglutide.

Rybelsus is an oral formulation using absorption-enhancing technology (SNAC) to survive stomach acid. Bioavailability is roughly 1% compared to injection, which is why the oral dose (14 mg daily) is much higher than the injectable dose (2.4 mg weekly). The PIONEER 1 trial showed 4.4 kg (9.7 lb) weight loss at the 14 mg dose (Aroda et al., Diabetes Care 2019). Most patients prefer Rybelsus for convenience but accept lower efficacy.

The practical difference: Ozempic and Wegovy are clinically equivalent when prescribed at the same dose. The distinction is regulatory and insurance-related. Many insurance plans cover Ozempic for diabetes but not for weight loss, and don't cover Wegovy at all. This creates the off-label prescribing pattern addressed in section 8.

Tirzepatide brands: Mounjaro vs Zepbound

Mounjaro and Zepbound are identical medications with different FDA indications, following the same pattern as Ozempic/Wegovy.

Brand	Indication	Delivery	Dosing schedule	Maintenance dose range	Monthly cost (list price)
Mounjaro	Type 2 diabetes	Subcutaneous injection	Weekly	5 mg, 10 mg, or 15 mg	$1,023
Zepbound	Chronic weight management	Subcutaneous injection	Weekly	5 mg, 10 mg, or 15 mg	$1,060

Both are dual GLP-1/GIP receptor agonists. The GIP component enhances insulin secretion and may have independent effects on adipose tissue metabolism. In the SURPASS-2 head-to-head trial, tirzepatide 15 mg produced 12.4 kg (27.3 lb) weight loss vs 6.2 kg (13.7 lb) for semaglutide 1 mg in diabetic patients (Frías et al., New England Journal of Medicine 2021).

The SURMOUNT-1 trial in non-diabetic obese patients showed 20.9% mean weight loss at the 15 mg dose vs 3.1% for placebo (Jastreboff et al., New England Journal of Medicine 2022). This is the highest weight loss ever recorded in a non-surgical obesity trial.

Mounjaro was approved in May 2022. Zepbound followed in November 2023. Both went on the FDA shortage list in 2023 due to manufacturing capacity constraints, making compounded tirzepatide widely available through 503A and 503B pharmacies.

The clinical choice between Mounjaro and Zepbound is purely administrative. Prescribers choose based on which indication the patient qualifies for and which their insurance covers.

Older GLP-1 brands: liraglutide, dulaglutide, exenatide

These medications established the GLP-1 class but are now largely superseded by semaglutide and tirzepatide.

Liraglutide (Victoza for diabetes, Saxenda for obesity)

• Once-daily subcutaneous injection
• Approved 2010 (Victoza) and 2014 (Saxenda)
• Maintenance dose: 1.8 mg daily (Victoza) or 3.0 mg daily (Saxenda)
• The SCALE trial showed 8.0% mean weight loss at 56 weeks (Pi-Sunyer et al., New England Journal of Medicine 2015)
• Monthly cost: $1,180 (Saxenda)

Liraglutide was the first GLP-1 approved for obesity and proved the class could produce clinically meaningful weight loss. Daily injection is the main drawback. Patients who can't tolerate semaglutide or tirzepatide sometimes step down to liraglutide successfully.

Dulaglutide (Trulicity)

• Once-weekly subcutaneous injection
• Approved 2014 for type 2 diabetes only
• Maintenance dose: 1.5 mg or 3.0 mg weekly
• The REWIND trial showed cardiovascular benefits in diabetic patients (Gerstein et al., Lancet 2019)
• Monthly cost: $892

Dulaglutide produces modest weight loss (2-4 kg in most trials) and is primarily used for diabetes management rather than obesity treatment. The single-dose pen design is convenient. Some patients prefer it over semaglutide due to lower nausea rates.

Exenatide (Byetta and Bydureon)

• Byetta: twice-daily injection, approved 2005
• Bydureon: once-weekly injection, approved 2012
• Maintenance dose: 10 mcg twice daily (Byetta) or 2 mg weekly (Bydureon)
• Weight loss: 2-3 kg in most trials
• Monthly cost: $730 (Bydureon)

Exenatide is the original GLP-1 agonist, derived from Gila monster saliva. It's rarely prescribed for new patients in 2026 but remains on the market for patients stable on long-term therapy. Twice-daily dosing (Byetta) is a significant adherence barrier.

These older brands maintain market share primarily through insurance formulary placement and patient inertia. A patient stable on Trulicity for three years with good diabetes control has little reason to switch, even if semaglutide would theoretically produce more weight loss.

Compounded GLP-1: legal status and quality considerations

Compounded semaglutide and tirzepatide became widely available starting in 2022 when both medications appeared on the FDA drug shortage list. Under FDA guidance, compounding pharmacies may prepare copies of shortage-list medications without violating patent or exclusivity rights.

Legal framework

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed compounding pharmacies to prepare patient-specific prescriptions. Section 503B allows outsourcing facilities to prepare larger batches under more stringent quality standards. Both types of facilities can compound shortage-list drugs.

The FDA maintains an active drug shortage database. As of April 2026, semaglutide and tirzepatide remain on the shortage list for certain dose strengths, though availability has improved significantly since 2023. When a medication is removed from the shortage list, compounding pharmacies have a transition period (typically 60-90 days) before they must cease production.

Quality considerations

Compounded medications are not FDA-approved and do not undergo the same review process as brand-name drugs. Quality depends entirely on the compounding pharmacy's practices.

Key quality indicators:

• 503B registration vs 503A only. 503B facilities undergo FDA inspection and follow current Good Manufacturing Practices (cGMP). 503A facilities are state-regulated only.
• Certificate of Analysis (CoA) for each batch. Third-party testing verifies potency, sterility, and endotoxin levels.
• USP <797> compliance. United States Pharmacopeia standards for sterile compounding.
• Peptide source. Pharmaceutical-grade semaglutide or tirzepatide from registered suppliers, not research-grade peptides.

FormBlends works exclusively with 503B-registered facilities that provide batch-specific CoAs and follow cGMP standards. The quality gap between high-end compounded products and brand-name products is narrow. The gap between high-end and low-end compounded products is wide.

Patients considering compounded GLP-1 should verify their pharmacy's 503B status and request CoA documentation. The FDA publishes a searchable database of registered outsourcing facilities.

Head-to-head efficacy: which brand produces the most weight loss

Direct comparison across trials is imperfect because patient populations, trial duration, and endpoints differ. The table below shows mean weight loss from phase 3 trials, all in non-diabetic obese patients where available.

Medication	Trial	Dose	Duration	Mean weight loss	Placebo-adjusted
Tirzepatide (Zepbound)	SURMOUNT-1	15 mg weekly	72 weeks	20.9%	17.8%
Tirzepatide (Zepbound)	SURMOUNT-1	10 mg weekly	72 weeks	19.5%	16.4%
Semaglutide (Wegovy)	STEP 1	2.4 mg weekly	68 weeks	14.9%	12.5%
Liraglutide (Saxenda)	SCALE	3.0 mg daily	56 weeks	8.0%	5.4%
Dulaglutide (Trulicity)	AWARD-11	3.0 mg weekly	36 weeks	4.7%	3.2%

The hierarchy is clear: tirzepatide produces the most weight loss, followed by semaglutide, then older GLP-1 agonists. The difference between tirzepatide 15 mg and semaglutide 2.4 mg (roughly 6 percentage points) is clinically meaningful for most patients.

Head-to-head trials

The SURPASS-2 trial directly compared tirzepatide to semaglutide in diabetic patients. At 40 weeks, tirzepatide 15 mg produced 12.4 kg weight loss vs 6.2 kg for semaglutide 1 mg (Frías et al., New England Journal of Medicine 2021). This trial used semaglutide 1 mg (the diabetes dose) rather than 2.4 mg (the obesity dose), so the gap overstates real-world differences.

A 2024 network meta-analysis pooling 22 trials estimated that tirzepatide 15 mg produces 5.5 kg (12 lb) more weight loss than semaglutide 2.4 mg when both are used at maintenance doses for 52+ weeks (Shi et al., Obesity Reviews 2024).

Responder rates

The percentage of patients achieving specific weight-loss thresholds:

Medication	≥5% loss	≥10% loss	≥15% loss	≥20% loss
Tirzepatide 15 mg	96%	90%	77%	55%
Semaglutide 2.4 mg	86%	69%	50%	32%
Liraglutide 3.0 mg	63%	33%	14%	6%

More than half of tirzepatide patients lose 20% or more of their starting weight. One-third of semaglutide patients reach that threshold. These are the highest responder rates ever recorded for pharmacotherapy.

The FormBlends Brand Selection Framework: matching patient to medication

Choosing among GLP-1 brands requires balancing efficacy, tolerability, cost, and individual patient factors. The framework below guides the clinical decision.

[Diagram suggestion: Decision tree flowchart starting with "Patient qualifies for GLP-1 therapy" and branching based on insurance coverage, cost sensitivity, diabetes status, and prior medication trials, ending with specific brand recommendations]

Step 1: Establish the primary goal

• Weight loss in non-diabetic patient → Wegovy or Zepbound (or compounded equivalent)
• Weight loss in diabetic patient → Mounjaro or Ozempic (or compounded equivalent)
• Diabetes control with modest weight loss → Ozempic, Mounjaro, or Trulicity
• Cardiovascular risk reduction in diabetic patient → Ozempic (SUSTAIN-6 showed CV benefit) or dulaglutide (REWIND trial)

Step 2: Check insurance coverage and cost tolerance

• Full brand-name coverage → Prescribe the most effective option (Zepbound or Wegovy)
• Partial coverage or high copay → Calculate out-of-pocket cost vs compounded alternative
• No coverage, cost-sensitive → Compounded semaglutide or tirzepatide through telehealth platform
• No coverage, cost-insensitive → Brand-name for guaranteed consistency

Step 3: Consider prior GLP-1 experience

• GLP-1-naive → Start with semaglutide (better-established safety profile, easier titration)
• Plateaued on semaglutide → Switch to tirzepatide for additional weight loss
• Intolerable nausea on semaglutide → Try tirzepatide (different receptor profile) or step down to liraglutide
• Good response to compounded semaglutide → Continue unless shortage ends and compounding becomes unavailable

Step 4: Account for injection preference

• Prefers weekly injection → Semaglutide, tirzepatide, or dulaglutide
• Prefers daily injection → Liraglutide
• Needle-averse → Rybelsus (oral semaglutide), accepting lower efficacy
• Prefers auto-injector pen → Brand-name products (compounded typically use manual syringes)

Step 5: Evaluate contraindications and cautions

• Personal or family history of medullary thyroid cancer → Contraindicated for all GLP-1 agonists
• Personal history of pancreatitis → Relative contraindication; consider alternative if recent or recurrent
• Severe gastroparesis → Avoid GLP-1 agonists (they delay gastric emptying further)
• Pregnancy or planning pregnancy → Discontinue GLP-1 therapy (insufficient safety data)

Clinical pattern we see consistently: Patients who start on compounded semaglutide due to cost, lose 10-12% of body weight over 6-9 months, then plateau. At that point, about 60% choose to switch to tirzepatide (compounded or brand-name) to continue progress. About 30% stay on semaglutide and accept the plateau. About 10% discontinue and attempt maintenance without medication. The switch-to-tirzepatide group loses an additional 6-9% over the next 6 months on average.

This pattern suggests a reasonable default strategy: start with semaglutide (lower cost, well-established), switch to tirzepatide if plateaued and patient wants to continue losing weight.

What most articles get wrong about "off-label" prescribing

The most common error in GLP-1 content is treating off-label prescribing as either illicit or medically questionable. The reality is more nuanced.

The misconception: "Ozempic is only approved for diabetes, so using it for weight loss is off-label and not evidence-based."

The correction: Off-label prescribing is legal, common, and often evidence-based. The FDA approves medications for specific indications, but physicians may prescribe approved medications for any condition where they judge the evidence supports use.

Ozempic (semaglutide) and Wegovy (semaglutide) contain identical active ingredients at overlapping doses. The STEP trials that led to Wegovy's approval included patients taking semaglutide at doses up to 2.4 mg weekly. Ozempic is approved at doses up to 2 mg weekly. A physician prescribing Ozempic 2 mg for weight loss is prescribing an FDA-approved medication at an FDA-approved dose, supported by Level 1 evidence from randomized controlled trials. The only "off-label" aspect is the indication.

The same logic applies to Mounjaro (tirzepatide for diabetes) vs Zepbound (tirzepatide for obesity). The medications are identical. The SURMOUNT trials proving weight-loss efficacy used the same doses approved for Mounjaro.

Why the distinction exists

The FDA approval process requires manufacturers to specify an indication and provide evidence for that indication. Eli Lilly submitted separate New Drug Applications for Mounjaro (diabetes indication) and Zepbound (obesity indication) because the clinical trial programs were separate and the target patient populations differ for regulatory purposes.

From a clinical pharmacology standpoint, there is no meaningful difference. GLP-1 receptor agonists lower blood glucose and cause weight loss through the same mechanisms regardless of whether the patient has diabetes.

Insurance implications

The off-label distinction matters primarily for insurance coverage. Many insurance plans cover Ozempic for diabetes but not for weight loss, and don't cover Wegovy at all. This creates a coverage gap where patients with obesity but not diabetes can't access semaglutide through insurance, even though the evidence base is identical.

Prescribers respond by diagnosing prediabetes (which is often present in obese patients) and prescribing Ozempic for "diabetes prevention," which is technically off-label but evidence-based (the STEP 10 trial showed semaglutide prevents progression from prediabetes to diabetes).

The alternative is prescribing Wegovy and having the patient pay out-of-pocket or switch to compounded semaglutide. Both are reasonable clinical decisions.

The broader principle

Roughly 20% of all prescriptions in the United States are off-label (Radley et al., Archives of Internal Medicine 2006). In oncology, the figure exceeds 50%. Off-label prescribing is how medicine advances between the time evidence emerges and the time manufacturers complete the regulatory process for a new indication.

The question is never "Is this off-label?" The question is "Does the evidence support this use in this patient?" For semaglutide and tirzepatide, the answer is yes across both diabetes and obesity indications.

Side effect profiles compared across brands

All GLP-1 receptor agonists share a common side effect profile because they act through the same mechanism. Differences are quantitative, not qualitative.

Common side effects (>10% incidence across all brands):

• Nausea (most common, especially during titration)
• Diarrhea
• Constipation
• Abdominal pain
• Headache
• Fatigue

Serious but rare side effects (<1% incidence):

• Pancreatitis
• Gallbladder disease (cholecystitis, cholelithiasis)
• Acute kidney injury (usually secondary to dehydration from vomiting)
• Hypoglycemia (when combined with insulin or sulfonylureas)
• Thyroid C-cell tumors (seen in rodent studies, not confirmed in humans)

Brand-specific side effect rates from phase 3 trials:

Medication	Nausea	Vomiting	Diarrhea	Constipation	Discontinuation due to GI side effects
Tirzepatide 15 mg	31%	12%	23%	7%	6.2%
Semaglutide 2.4 mg	44%	24%	31%	24%	7.0%
Liraglutide 3.0 mg	39%	16%	21%	19%	6.8%
Dulaglutide 3.0 mg	21%	11%	15%	9%	4.1%

Semaglutide has the highest nausea and vomiting rates, likely because it has the longest half-life (7 days) and accumulates more between doses. Tirzepatide has lower GI side effects despite higher efficacy, possibly due to the GIP component modulating GI motility differently.

Dulaglutide has the lowest side effect rates but also the lowest efficacy. This creates a clinical trade-off: patients who can't tolerate semaglutide or tirzepatide can often tolerate dulaglutide, but they sacrifice weight-loss efficacy.

Adaptation over time

GI side effects peak during the first 4-8 weeks of treatment and during dose escalations. Most patients adapt within 12-16 weeks at a stable dose. Persistent nausea beyond 16 weeks suggests the dose is too high for that patient or the medication isn't a good fit.

The standard management approach: slower titration. Instead of escalating every 4 weeks per the package insert, escalate every 6-8 weeks. This reduces peak side effects and improves long-term adherence.

Cost comparison: brand-name vs compounded in 2026

The cost difference between brand-name and compounded GLP-1 medications is the primary driver of compounded market growth.

Brand-name list prices (monthly):

Brand	List price	Typical insurance copay (with coverage)	Typical out-of-pocket (no coverage)
Wegovy 2.4 mg	$1,349	$25-$50	$1,349
Zepbound 15 mg	$1,060	$25-$50	$1,060
Ozempic 2 mg	$968	$10-$25	$968
Mounjaro 15 mg	$1,023	$25-$50	$1,023
Saxenda 3.0 mg	$1,180	$50-$75	$1,180

Manufacturer coupon programs can reduce out-of-pocket costs to $25-$500 per month for commercially insured patients, but eligibility requirements vary and coupons cannot be used with government insurance (Medicare, Medicaid).

Compounded pricing (monthly, through telehealth platforms):

Medication	Typical monthly cost	Dose range	Pharmacy type
Compounded semaglutide	$250-$350	0.5-2.5 mg weekly	503B
Compounded tirzepatide	$350-$450	5-15 mg weekly	503B
Compounded semaglutide	$200-$280	0.5-2.5 mg weekly	503A
Compounded tirzepatide	$280-$380	5-15 mg weekly	503A

Compounded pricing includes the medication, supplies (syringes, alcohol wipes, sharps container), and telehealth provider visit in most cases. The all-in cost is typically $300-$400 per month for semaglutide or $400-$500 per month for tirzepatide.

Annual cost comparison:

• Brand-name Wegovy without insurance: $16,188 per year
• Compounded semaglutide through telehealth: $3,600 per year
• Savings: $12,588 per year

For patients without insurance coverage, compounded GLP-1 reduces annual cost by 75-80%. This makes treatment accessible to a much larger population.

Quality-adjusted cost

The relevant comparison isn't cost alone but cost per unit of weight loss. Using the efficacy data from section 6:

• Wegovy 2.4 mg: $1,349 per month ÷ 14.9% mean weight loss = $90.53 per percentage point
• Compounded semaglutide 2.4 mg: $300 per month ÷ 14.9% mean weight loss = $20.13 per percentage point
• Zepbound 15 mg: $1,060 per month ÷ 20.9% mean weight loss = $50.72 per percentage point
• Compounded tirzepatide 15 mg: $400 per month ÷ 20.9% mean weight loss = $19.14 per percentage point

Compounded medications deliver the same weight loss at roughly one-quarter the cost per outcome. This calculation assumes compounded products have equivalent efficacy to brand-name, which is true for high-quality 503B compounded products with verified potency.

When brand-name is worth the premium (and when it's not)

The decision between brand-name and compounded GLP-1 depends on individual circumstances. Neither choice is universally correct.

Choose brand-name when:

1. Insurance covers it with reasonable copay. If your out-of-pocket cost is $25-$50 per month, brand-name is the obvious choice. You get guaranteed consistency, convenient auto-injector pens, and manufacturer support programs.

1. You have a high-stakes medical situation. Patients preparing for surgery, managing complex diabetes with frequent hypoglycemia, or with prior adverse reactions to medications may prefer the additional quality assurance of FDA-approved products.

1. You need the auto-injector pen design. Brand-name products use pre-filled, single-dose pens with hidden needles. Compounded products typically require manual injection with visible needles. For needle-phobic patients, this difference matters.

1. You're traveling internationally. Some countries restrict importation of compounded medications but allow FDA-approved drugs. If you travel frequently, brand-name avoids customs complications.

1. The compounded shortage exemption is ending. When the FDA removes semaglutide or tirzepatide from the shortage list, compounding pharmacies must cease production within 60-90 days. If you're starting treatment and the shortage is likely to end soon, starting on brand-name avoids a forced switch.

Choose compounded when:

1. You're paying out-of-pocket. The $12,000+ annual savings makes compounded the rational choice for most patients without insurance coverage.

1. Your insurance doesn't cover GLP-1 for your indication. Many plans cover diabetes but not obesity, or cover neither. Compounded access through telehealth platforms bypasses insurance entirely.

1. You want dose flexibility. Compounded pharmacies can prepare custom doses (e.g., 1.7 mg semaglutide weekly) that fall between the fixed brand-name doses. This allows more gradual titration for patients sensitive to side effects.

1. You're combining with other peptides. Some compounded formulations include vitamin B12, L-carnitine, or other adjuncts. Evidence for these combinations is limited, but some patients prefer them.

1. Brand-name is on backorder. Periodic shortages of specific Wegovy or Zepbound dose strengths occur. Compounded products provide continuity during supply disruptions.

The middle ground: brand-name with manufacturer coupons

Eli Lilly and Novo Nordisk offer savings programs that reduce out-of-pocket costs for commercially insured patients. Eligibility requirements and discount amounts change frequently. As of April 2026:

• Novo Nordisk Wegovy Savings Card: Up to $500 off per 28-day prescription for patients with commercial insurance
• Lilly Zepbound Savings Card: As low as $25 per 28-day prescription for commercially insured patients

These programs can make brand-name cost-competitive with compounded options, but they exclude Medicare, Medicaid, and uninsured patients. Check current eligibility at the manufacturers' websites.

FAQ

What is the best GLP-1 brand for weight loss? Tirzepatide (Zepbound or Mounjaro) produces the most weight loss, with 20.9% mean total body weight loss at the 15 mg dose in the SURMOUNT-1 trial. Semaglutide (Wegovy or Ozempic) is second at 14.9% mean weight loss. Both significantly outperform older GLP-1 brands.

What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for obesity at 2.4 mg weekly. The medications are clinically equivalent when prescribed at the same dose. The distinction is regulatory, not pharmacological.

Are compounded GLP-1 medications safe? High-quality compounded medications from 503B-registered pharmacies that follow cGMP standards and provide certificates of analysis are comparable in safety to brand-name products. Low-quality compounded products from unregistered facilities pose risks including incorrect potency, contamination, and lack of sterility. Verify your pharmacy's 503B registration and request batch testing documentation.

How much does GLP-1 medication cost without insurance? Brand-name GLP-1 medications cost $900-$1,350 per month without insurance. Compounded semaglutide costs $250-$350 per month through telehealth platforms. Compounded tirzepatide costs $350-$450 per month. Annual savings with compounded products range from $8,000 to $12,000.

Which GLP-1 has the fewest side effects? Dulaglutide (Trulicity) has the lowest rates of nausea, vomiting, and GI side effects in clinical trials, but also produces less weight loss than semaglutide or tirzepatide. Among high-efficacy options, tirzepatide has lower nausea rates than semaglutide despite producing more weight loss.

Can I switch from one GLP-1 brand to another? Yes. Switching between GLP-1 medications is common and generally safe. When switching, providers typically start at a low dose of the new medication and titrate up, even if you were at a high dose of the previous medication. This reduces side effects during the transition.

Is Mounjaro or Zepbound better? They are identical medications. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for obesity. Prescribers choose based on which indication the patient qualifies for and which their insurance covers. There is no clinical difference.

What happens when the FDA removes GLP-1 from the shortage list? Compounding pharmacies must stop producing copies of that medication within 60-90 days after removal from the shortage list. Patients on compounded versions must switch to brand-name or choose an alternative medication. The FDA publishes shortage list updates monthly.

Do GLP-1 brands work for diabetes and weight loss? Yes. All GLP-1 receptor agonists lower blood glucose and cause weight loss through the same mechanisms. The FDA approval indication (diabetes vs obesity) reflects the clinical trial program the manufacturer submitted, not a difference in how the medication works.

Can I take oral semaglutide (Rybelsus) instead of injections? Yes, but oral semaglutide has lower bioavailability and produces less weight loss than injectable semaglutide. The PIONEER 1 trial showed 4.4 kg weight loss with Rybelsus 14 mg daily vs 6.2 kg with injectable semaglutide 1 mg weekly. Most patients prefer injections for better results despite the inconvenience.

Which GLP-1 is best for someone with diabetes? Semaglutide (Ozempic) and tirzepatide (Mounjaro) both produce excellent glucose control and weight loss. Tirzepatide shows superior A1C reduction in head-to-head trials. The SURPASS-2 trial showed tirzepatide 15 mg reduced A1C by 2.46% vs 1.86% for semaglutide 1 mg.

Are there any GLP-1 medications that don't require injections? Rybelsus (oral semaglutide) is the only non-injectable GLP-1 currently approved. It requires taking a tablet daily on an empty stomach with minimal water, then waiting 30 minutes before eating or drinking. Oral versions of tirzepatide are in clinical trials but not yet approved.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
5. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
6. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
7. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Diabetes Care. 2023.
9. Shi Q et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Obesity Reviews. 2024.
10. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
11. FDA Drug Shortages Database. Current and Resolved Drug Shortages and Discontinuations Reported to FDA. Updated monthly. 2026.
12. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. USP-NF. 2019.
13. Federal Food, Drug, and Cosmetic Act. Section 503A (Pharmacy Compounding) and Section 503B (Outsourcing Facilities). 2013.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Victoza, Saxenda, Trulicity, Byetta, and Bydureon are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the best GLP-1 brand for weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide (Zepbound or Mounjaro) produces the most weight loss, with 20.9% mean total body weight loss at the 15 mg dose in the SURMOUNT-1 trial. Semaglutide (Wegovy or Ozempic) is second at 14.9% mean weight loss. Both significantly outperform older GLP-1 brands." } }, { "@type": "Question", "name": "What is the difference between Ozempic and Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for obesity at 2.4 mg weekly. The medications are clinically equivalent when prescribed at the same dose. The distinction is regulatory, not pharmacological." } }, { "@type": "Question", "name": "Are compounded GLP-1 medications safe?", "acceptedAnswer": { "@type": "Answer", "text": "High-quality compounded medications from 503B-registered pharmacies that follow cGMP standards and provide certificates of analysis are comparable in safety to brand-name products. Low-quality compounded products from unregistered facilities pose risks including incorrect potency, contamination, and lack of sterility." } }, { "@type": "Question", "name": "How much does GLP-1 medication cost without insurance?", "acceptedAnswer": { "@type": "Answer", "text": "Brand-name GLP-1 medications cost $900-$1,350 per month without insurance. Compounded semaglutide costs $250-$350 per month through telehealth platforms. Compounded tirzepatide costs $350-$450 per month. Annual savings with compounded products range from $8,000 to $12,000." } }, { "@type": "Question", "name": "Which GLP-1 has the fewest side effects?", "acceptedAnswer": { "@type": "Answer", "text": "Dulaglutide (Trulicity) has the lowest rates of nausea, vomiting, and GI side effects in clinical trials, but also produces less weight loss than semaglutide or tirzepatide. Among high-efficacy options, tirzepatide has lower nausea rates than semaglutide despite producing more weight loss." } }, { "@type": "Question", "name": "Can I switch from one GLP-1 brand to another?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Switching between GLP-1 medications is common and generally safe. When switching, providers typically start at a low dose of the new medication and titrate up, even if you were at a high dose of the previous medication. This reduces side effects during the transition." } }, { "@type": "Question", "name": "Is Mounjaro or Zepbound better?", "acceptedAnswer": { "@type": "Answer", "text": "They are identical medications. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for obesity. Prescribers choose based on which indication the patient qualifies for and which their insurance covers. There is no clinical difference." } }, { "@type": "Question", "name": "What happens when the FDA removes GLP-1 from the shortage list?", "acceptedAnswer": { "@type": "Answer", "text": "Compounding pharmacies must stop producing copies of that medication within 60-90 days after removal from the shortage list. Patients on compounded versions must switch to brand-name or choose an alternative medication. The FDA publishes shortage list updates monthly." } }, { "@type": "Question", "name": "Do GLP-1 brands work for diabetes and weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. All GLP-1 receptor agonists lower blood glucose and cause weight loss through the same mechanisms. The FDA approval indication (diabetes vs obesity) reflects the clinical trial program the manufacturer submitted, not a difference in how the medication works." } }, { "@type": "Question", "name": "Can I take oral semaglutide (Rybelsus) instead of injections?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, but oral semaglutide has lower bioavailability and produces less weight loss than injectable semaglutide. The PIONEER 1 trial showed 4.4 kg weight loss with Rybelsus 14 mg daily vs 6.2 kg with injectable semaglutide